Ningetinib is a targeted oncology therapy primarily used for treating non-small cell lung cancer (NSCLC) in patients with ROS1 and RET gene mutations or fusions. It functions as a selective tyrosine kinase inhibitor, specifically targeting ROS1 and RET receptors to block signaling pathways that drive tumor growth, proliferation, and metastasis. Clinical studies demonstrate its efficacy in slowing disease progression, improving patient outcomes, and enhancing quality of life. It is also under investigation for other ROS1- or RET-altered cancers. When combined with other therapies, it may increase treatment effectiveness. Its precise targeting of cancer cells helps reduce side effects compared to conventional chemotherapy.